Trials / Sponsors / Alto Neuroscience
Alto Neuroscience
Industry · 11 registered clinical trials — 3 currently recruiting.
| Status | Trial | Phase | Started |
|---|---|---|---|
| Recruiting | ALTO-100 in Bipolar Disorder With Depression (BD-D) Bipolar Disorder I or II With a Major Depressive Episode | Phase 2 | 2024-10-02 |
| Recruiting | Study of ALTO-101 in Patients With Schizophrenia Schizophrenia, Cognitive Impairment | Phase 2 | 2024-06-11 |
| Completed | PD, PK, and Safety of ALTO-203 in Patients With MDD Major Depressive Disorder, Anhedonia | Phase 2 | 2024-03-25 |
| Recruiting | Study of ALTO-300 in MDD Major Depressive Disorder | Phase 2 | 2023-06-08 |
| Completed | Phase 2b Study of ALTO-100 in MDD Major Depressive Disorder | Phase 2 | 2023-01-10 |
| Completed | Pilot Decentralized Trial Major Depressive Disorder | Phase 2 | 2022-06-01 |
| Completed | ALTO-300 in Depression (ALTO-300-004) Major Depressive Disorder | Phase 2 | 2022-02-03 |
| Completed | ALTO-100 in MDD and/or PTSD Major Depressive Disorder, Post Traumatic Stress Disorder | Phase 2 | 2021-12-20 |
| Completed | ALTO-300 in Depression Major Depressive Disorder | Phase 2 | 2021-12-13 |
| Withdrawn | Leveraging EEG for Antidepressant Prediction With Sertraline and Escitalopram Major Depressive Disorder | Phase 4 | 2020-10-15 |
| Withdrawn | Leveraging EEG for Antidepressant Prediction With Duloxetine and Bupropion Major Depressive Disorder | Phase 4 | 2020-10-15 |